Sleepio is a revolutionary digital therapeutic for insomnia

Lasting recovery from insomnia that’s available anytime, anywhere.

Illustration of Sleepio's sleep diary

In a clinical trial, 76% of patients experienced clinically significant improvement in insomnia

54%

reduction in time to fall asleep.1

62%

less time awake at night.1

45%

better functioning the next day.1

For the past decade, we’ve been putting Sleepio to the test in gold-standard clinical trials.

Sleepio use was shown to lower health care costs by $1,677 per employee

A health economic evaluation with IBM Watson Health and a Fortune 500 employer demonstrated that Sleepio generated a significant per-employee health care cost reduction.2

Graph depicting Sleepio's health economic results — at 18 month follow-up, Sleepio users' health care costs were $1,677 lower than the control group, on average.

Sleepio delivers meaningful, lasting results

Sleepio addresses unique needs with a personalized program, featuring sessions with step-by-step guidance through evidence-based techniques. In about 20 minutes per week, individuals can quiet their racing minds, reshape behaviors, and get better sleep.

Image depicting the wind-down, before-sleep schedule screen from Sleepio.

Personalized therapeutic content

Sleepio adjusts therapeutic content to each individual’s needs and offers additional tools and insights when needed.

Image depicting Sleepio's "Help me get to sleep" menu of sleep aids.

Help at any time, day or night

When it’s needed the most, Sleepio is instantly accessible and ready to check in, practice, or try a new technique.

Image depicting a Sleepio progress chart.

Progress tracking

Sleepio provides personalized goal setting, a detailed sleep diary, and helps track progress over time.

What Sleepio users say

Sleepio has made a huge change in my ability to fall asleep quickly and have restful sleep.

Member in UKSeptember, 2020

Using this program is like having a friend that understands your anxiety around sleep and helps you through it.

Member in AfricaNovember, 2020

I’ve had insomnia for 18 years. Sleepio has brought my average sleep from two hours a night to seven hours a night.

Member in UKOctober, 2020

I can’t believe I learned so much in such a short time after suffering for decades. This program is brilliant.

Member in USApril, 2021

Poor sleep affects up to 35% of workers

Over a third of US workers suffer from poor sleep, and as a result are at increased risk of reduced workplace performance and functioning, including reduced focus, increased risk of injury, and poorer mental health.3-6 Though accessible, commonly-prescribed sleep medications can cause side effects like drowsiness and memory loss.7

1. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.
2. Miller, C. B., Carl, J. R., Henry, A. L., Baker, L. (2020). A health economic evaluation of Sleepio at a Fortune 500 company. Retrieved from: https://go.bighealth.com/report/health-economic-evaluation.
3. CDC – Data and Statistics – Sleep and Sleep Disorders. (2017). CDC. https://www.cdc.gov/sleep/data_statistics.html
4. Varkevisser, M., & Kerkhof, G. A. (2005). Chronic insomnia and performance in a 24‐h constant routine study. Journal of Sleep Research, 14(1), 49-59.
5. Shahly, V., Berglund, P. A., Coulouvrat, C., Fitzgerald, T., Hajak, G., Roth, T., … & Kessler, R. C. (2012). The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Archives of general psychiatry, 69(10), 1054-1063.
6. Hertenstein, E., Feige, B., Gmeiner, T., Kienzler, C., Spiegelhalder, K., Johann, A., … & Baglioni, C. (2019). Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep medicine reviews, 43, 96-105.
7. Brandt, J., & Leong, C. (2017). Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs in R&D, 17(4), 493-507.